FDA Seeks Vet Drug Paperwork: Moo-ving Along Smoothly
Published Date: 6/16/2025
Notice
Summary
The FDA is asking for approval to collect new information about animal drugs and veterinary files. This affects drug makers and vets who need to share important details to keep animal medicines safe and effective. They’re aiming to make the process smoother without extra costs, and the review is happening now, so stay tuned for updates!
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
FDA seeks OMB review of animal drug data collection
The FDA submitted a proposed collection of information about new animal drugs and veterinary master files to the Office of Management and Budget for review and clearance under the Paperwork Reduction Act of 1995. This affects drug makers and veterinarians who must provide or share information about animal medicines, and the agency says it aims to streamline the process without adding extra costs.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13820 — Determination That TOVALT ODT (Zolpidem Tartrate) Orally Disintegrating Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that TOVALT ODT tablets (5 mg and 10 mg) weren’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, making it easier and cheaper for people who need this sleep aid. If approved, more affordable options could hit the shelves soon, helping patients and saving money.
2026-13778 — Medical Device User Fee Amendments; Public Meeting; Request for Comments
The FDA is planning a public meeting on August 5, 2026, to talk about renewing fees that medical device makers pay to help speed up device reviews from 2028 to 2032. This affects companies making medical devices and could impact how much they pay and how fast their products get approved. The current fee program ends in September 2027, so the FDA wants your thoughts before finalizing new rules and fees.
2026-13716 — New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor
The FDA just updated the rules for new animal drugs, approving several new and generic medicines for pets and farm animals from early 2026. These changes help keep animal treatments safe and effective, and the updates take effect right away on July 7, 2026. If you’re a drug maker or animal caretaker, these approvals and sponsor changes could impact what medicines are available and when.
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
Previous / Next Documents
Previous: 2025-10883 — Self-Regulatory Organizations; Nasdaq Stock Market LLC; Order Instituting Proceedings To Determine Whether To Approve or Disapprove a Proposed Rule Change, as Modified by Amendment No. 1, To List and Trade Shares of the Canary HBAR ETF Under Nasdaq Rule 5711(d) (Commodity Based Trust Shares)
The SEC is deciding whether to approve Nasdaq’s plan to list and trade shares of the Canary HBAR ETF, a new fund tied to the cryptocurrency Hedera Hashgraph. This affects investors interested in crypto-based ETFs and could open fresh trading opportunities soon. The SEC’s decision deadline is June 11, 2025, so keep an eye out for updates that might impact your portfolio.
Next: 2025-10885 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarket Surveillance of Medical Devices
The FDA wants your thoughts on how they collect info about medical devices after they hit the market. This helps keep devices safe and working well for everyone. If you make or use these devices, now’s the time to speak up before the 60-day comment window closes—no big costs, just better safety checks!